• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

头孢噻肟诱导的免疫性溶血性贫血,原因是抗体在体外通过不止一种机制发生反应。

Cefotaxime-induced immune hemolytic anemia due to antibodies reacting in vitro by more than one mechanism.

作者信息

Shulman I A, Arndt P A, McGehee W, Garratty G

机构信息

Blood Bank and Transfusion Medicine Unit, Los Angeles County-University of Southern California Medical Center.

出版信息

Transfusion. 1990 Mar-Apr;30(3):263-6. doi: 10.1046/j.1537-2995.1990.30390194351.x.

DOI:10.1046/j.1537-2995.1990.30390194351.x
PMID:2316002
Abstract

Until recently, all cephalosporin-induced immune hemolytic anemias appeared to react by a "penicillin-type" drug adsorption mechanism, and hemolysis was extravascular. In 1987 and 1988, the first two cases of cephalosporin-induced immune hemolytic anemia with intravascular hemolysis associated with a so-called immune complex mechanism were reported. This report describes a case of extravascular hemolysis due to a third-generation cephalosporin, cefotaxime, which, to the authors' knowledge, is the first to show in vitro characteristics of both the drug adsorption and the so-called immune complex mechanisms.

摘要

直到最近,所有头孢菌素引起的免疫性溶血性贫血似乎都是通过“青霉素型”药物吸附机制发生反应的,溶血发生在血管外。1987年和1988年,有报道称首例两例头孢菌素引起的免疫性溶血性贫血伴有血管内溶血,与所谓的免疫复合物机制有关。本报告描述了一例由第三代头孢菌素头孢噻肟引起的血管外溶血病例,据作者所知,这是首例在体外表现出药物吸附和所谓免疫复合物机制特征的病例。

相似文献

1
Cefotaxime-induced immune hemolytic anemia due to antibodies reacting in vitro by more than one mechanism.头孢噻肟诱导的免疫性溶血性贫血,原因是抗体在体外通过不止一种机制发生反应。
Transfusion. 1990 Mar-Apr;30(3):263-6. doi: 10.1046/j.1537-2995.1990.30390194351.x.
2
First two cases of immune hemolytic anemia associated with ceftizoxime.
Transfusion. 1999 Aug;39(8):838-44. doi: 10.1046/j.1537-2995.1999.39080838.x.
3
'Immune complex' mediated intravascular hemolysis due to IgM cephalosporin-dependent antibody.由IgM头孢菌素依赖性抗体介导的“免疫复合物”型血管内溶血。
Transfusion. 1987 Nov-Dec;27(6):460-3. doi: 10.1046/j.1537-2995.1987.27688071694.x.
4
How we investigate drug-induced immune hemolytic anemia.我们如何调查药物性免疫性溶血性贫血。
Immunohematology. 2014;30(2):85-94.
5
[Immunomechanisms in drug-induced hemolytic anemias].[药物性溶血性贫血的免疫机制]
Acta Med Austriaca. 1979;6(5):180-2.
6
Drug-induced immune hemolytic anemia.药物性免疫性溶血性贫血
Am J Med. 1975 Mar;58(3):398-407. doi: 10.1016/0002-9343(75)90606-3.
7
Drug-induced immune hemolytic anemia: the last 30 years of changes.药物性免疫性溶血性贫血:过去30年的变化
Immunohematology. 2014;30(2):44-54.
8
Ceftizoxime-induced hemolysis secondary to combined drug adsorption and immune-complex mechanisms.
Transfusion. 2001 Jul;41(7):893-7. doi: 10.1046/j.1537-2995.2001.41070893.x.
9
Drugs that have been shown to cause drug-induced immune hemolytic anemia or positive direct antiglobulin tests: some interesting findings since 2007.已被证明可导致药物性免疫性溶血性贫血或直接抗球蛋白试验呈阳性的药物:2007年以来的一些有趣发现。
Immunohematology. 2014;30(2):66-79.
10
Cefotetan-induced immune hemolytic anemia.头孢替坦诱发的免疫性溶血性贫血。
Clin Infect Dis. 1992 Nov;15(5):863-5. doi: 10.1093/clind/15.5.863.

引用本文的文献

1
Case Report: First Case of Cefotaxime-Sulbactam-Induced Acute Intravascular Hemolysis in a Newborn With ABO Blood Type Incompatibility by the Mechanism of Non-Immunologic Protein Adsorption.病例报告:头孢噻肟舒巴坦引起的非免疫性蛋白吸附机制导致 ABO 血型不合新生儿急性血管内溶血性贫血的首例报告
Front Immunol. 2021 Dec 22;12:698541. doi: 10.3389/fimmu.2021.698541. eCollection 2021.
2
When a transfusion in an emergency service is not really urgent: hyperhaemolysis syndrome in a child with sickle cell disease.当急诊服务中的输血并非真正紧急时:镰状细胞病患儿的高溶血综合征
BMJ Case Rep. 2018 Mar 27;2018:bcr-2017-223209. doi: 10.1136/bcr-2017-223209.
3
Cefotaxime. A reappraisal of its antibacterial activity and pharmacokinetic properties, and a review of its therapeutic efficacy when administered twice daily for the treatment of mild to moderate infections.
头孢噻肟。对其抗菌活性和药代动力学特性的重新评估,以及对其每日两次给药治疗轻至中度感染时的治疗效果的综述。
Drugs. 1997 Mar;53(3):483-510. doi: 10.2165/00003495-199753030-00009.
4
Adverse effects of newer cephalosporins. An update.新型头孢菌素的不良反应。最新进展。
Drug Saf. 1993 Aug;9(2):132-42. doi: 10.2165/00002018-199309020-00005.
5
Cefotaxime. An update of its pharmacology and therapeutic use.头孢噻肟。其药理学与治疗应用的最新进展。
Drugs. 1990 Oct;40(4):608-51. doi: 10.2165/00003495-199040040-00008.